Table 4.
Univariable Cox regression analysis for PFS and OS.
| Progression free survival | Overall survival | ||||||
|---|---|---|---|---|---|---|---|
| unadjusted HR | 95%CI | P | unadjusted HR | 95%CI | P | ||
| ECOG PS | Stage | ||||||
| 2 | 1 | Recurrence | 1 | ||||
| 0 | 0.165 | 0.051-0.528 | 0.002 | IIIB | 1.747 | 0.960-3.178 | 0.068 |
| 1 | 0.240 | 0.085-0.673 | 0.007 | IV | 1.153 | 0.678-1.961 | 0.599 |
| NLR6w | Mutation type | ||||||
| Up | 1 | Wild-type | 1 | ||||
| Down | 0.604 | 0.408-0.894 | 0.012 | EGFR | 1.779 | 0.993-3.189 | 0.053 |
| Hb6w | KRAS | 1.145 | 0.416-3.146 | 0.793 | |||
| Up | 1 | PLR0w | |||||
| Down | 0.682 | 0.446-1.045 | 0.079 | Up | 1 | ||
| CEA6w | Down | 0.679 | 0.439-1.052 | 0.083 | |||
| Up | 1 | CEA0w | |||||
| Down | 0.510 | 0.344-0.756 | 0.001 | Up | 1 | ||
| NLR12w | Down | 0.620 | 0.393-0.977 | 0.039 | |||
| Up | 1 | CEA6w | |||||
| Down | 0.536 | 0.357-0.802 | 0.002 | Up | 1 | ||
| CEA12w | Down | 0.497 | 0.320-0.771 | 0.002 | |||
| Up | 1 | NSE6w | |||||
| Down | 0.413 | 0.276-0.618 | 0.000 | Up | 1 | 0.007 | |
| Radiotherapy | Down | 0.537 | 0.340-0.846 | ||||
| Up | 1 | CEA12w | |||||
| Down | 0.536 | 0.359-0.799 | 0.002 | Up | 1 | ||
| Down | 0.662 | 0.424-1.033 | 0.069 | ||||
| NSE12w | |||||||
| Up | 1 | ||||||
| Down | 0.573 | 0.356-0.923 | 0.022 | ||||
ECOG, Eastern Cooperative Oncology Group; PS, performance status; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; Hb, hemoglobin; CEA, carcinoembryonic antigen; NSE, neuron-specific enolase.